IL-18对9L胶质瘤细胞表面分子表达影响的体内外研究  

Effect of IL-18 on expression of molecule on surface of 9L in vitro and in vivo

作　　者：宋杨英[1] 张建军[1] 陈颖 单保恩[2] 刘英姿[3] 

机构地区：[1]河北省玉田县医院检验科,玉田064100 [2]河北医科大学第四医院科研中心,石家庄050011 [3]河北医科大学第四医院神经外科,石家庄050011

出　　处：《中国免疫学杂志》2014年第6期749-753,共5页Chinese Journal of Immunology

摘　　要：目的:探讨IL-18转染大鼠胶质瘤细胞9L后,对其表面MHCⅠ、Ⅱ类分子及共刺激分子CD80、CD86表达的影响,以明确IL-18对胶质瘤细胞免疫原性及抗原递呈能力的影响。方法:以逆转录病毒为载体将外源性IL-18基因转染至9L细胞内,建立能够稳定表达IL-18的细胞(9L/IL-18),同时建立只转空病毒载体的对照细胞9L/LXSN。用流式细胞分析技术检测9L/IL-18、9L/LXSN及9L细胞表面MHCⅠ、Ⅱ类分子及共刺激分子CD80、CD86的表达;用立体定向仪将9L/IL-18、9L/LXSN及9L细胞分别接种到F344大鼠颅内,建立大鼠胶质瘤模型,建模14天后处死大鼠,用流式细胞分析技术检测肿瘤组织细胞表面MHCⅠ、Ⅱ类分子及CD80、CD86的表达。结果:在体外,IL-18转染后(9L/IL-18)细胞表面MHCⅠ、Ⅱ类分子及CD80、CD86的表达分别为(10.9±1.44)%、(0.61±0.14)%、(1.01±0.14)%、(0.57±0.11)%与其他两组(9L/LXSN及9L)相比无显著差异(P>0.05);在体内,接种9L/IL-18细胞组大鼠肿瘤组织细胞表面MHCⅠ类分子及CD80、CD86的表达分别为(67.51±1.40)%、(12.51±1.57)%、(6.95±0.56)%,均高于其他两组,差异有统计学意义(P<0.05),MHCⅡ类分子表达(3.76±0.26)%与其他两组相比差异无统计学意义(P>0.05)。结论:在体外,IL-18不影响9L细胞免疫原性;在体内,IL-18可提高9L细胞免疫原性及抗原递呈能力,增强机体对胶质瘤的免疫反应性。Objective：To explore the influence of IL-18 on the expression of MHCⅠ,MHCⅡ,CD80,CD86 on the surface of 9L cells,to identify the effect of IL-18 on the immunogenicity and the efficiency of tumor antigen presentation of 9L.Methods：Retroviruses were used to transduce the mIL-18 gene into rat glioma cells and the cell clones （9L/IL-18） which steadily expressing mIL-18 gene were obtained ,and got the control cells of 9L/LXSN by the same method.The expression of MHCⅠ,MHCⅡ,CD80,CD86 on the cell surface were assessed by flow cytometry.The cell suspension of 9L/IL-18,9L/LXSN and 9L cells were inoculated into the brain of F344 rat to establish the animal models by the stereotactic technique ,got the tumor tissues to analyze the expression of MHCⅠ, MHCⅡ,CD80 and CD86 on the surface of tumor cells after 14 days.Results：The expression of MHCⅠ,MHCⅡ,CD80 and CD86 on the surface of 9L/IL-18 were （10.9±1.44）%,（0.61±0.14）%,（1.01±0.14）%,（0.57±0.11）% ; had no significant differences with the others in vitro （P〉0.05）;while the expression of MHCⅠ,CD80 and CD86 on the surface of 9L/IL-18 were（67.51± 1.40）%,（12.51±1.57）%,（6.95±0.56）%which were higher than 9L/LXSN and 9L cells （P〈0.05）,the expressions of MHCⅡwere no significant difference（P〉0.05） in vivo.Conclusion： IL-18 did not affect the immunogenicity of 9L in vitro,but improve the immunogenicity and tumor antigen presentation in vivo.

关 键 词：IL-18 胶质瘤 MHCⅠ MHCⅡ CD80 CD86 

分 类 号：R739.41[医药卫生—肿瘤]